Indapamid LPH

Quick links to important sections

Indapamid LPH

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indapamid LPH

Property Description
Active ingredient Indapamide
Form Oral Tablet
Pharmacological class Thiazide-like Diuretic
Common use Managing high blood pressure (Antihypertensive)
Origin Synthetic compound (Sulfonamide derivative)

Indapamid LPH: Defining the Medicine and its Form

Indapamid LPH is a prescription-only medicine presented as an oral tablet containing the single active ingredient, Indapamide. The product is a single-ingredient formulation designed for effective systemic absorption through oral administration. Indapamide is a synthetic compound chemically derived from the sulfonamide group and is classified as a sulfonamide derivative. The use of a simple, uniform tablet ensures a standardized and stable method of delivering the active substance into the body after swallowing.

Pharmacological Classification and General Purpose

Indapamide is placed within the broader pharmacological category of diuretics, and more specifically, it is defined as a thiazide-like diuretic and functions as an antihypertensive agent. This classification means the medicine is recognized as a tool for the long-term management of elevated blood pressure, which is its common therapeutic use. Indapamide is used for its sustained action in lowering blood pressure. The general purpose of the medicine is to reduce the pressure against arterial walls, thereby supporting overall cardiovascular function. This is achieved through its capacity to promote fluid and salt excretion, combined with its direct vasoactive properties which help relax blood vessels.

Regulatory References

  1. NIH MedlinePlus Drug Information
  2. DailyMed Indapamide Label (NLM)

What side effects are possible with Indapamid LPH?

Possible Side Effects and Safety Information

Indapamide's official safety profile, as documented in regulatory sources, is largely defined by its function as a thiazide-like diuretic, focusing on fluid and electrolyte balance and the possibility of hypersensitivity reactions related to its sulfonamide chemical class. Side effects are classified by frequency and associated with various System Organ Classes (SOC).

Common adverse reactions, defined as affecting up to 1 in 10 people, primarily involve Metabolism and Nutrition Disorders, such as hypokalaemia (low potassium levels), and Skin and Subcutaneous Tissue Disorders, most frequently presenting as a maculopapular rash. Non-specific effects like headache and fatigue are also listed as common. Uncommon effects include hyponatraemia (low sodium) and orthostatic hypotension.

Serious Adverse Reactions are typically very rare (affecting up to 1 in 10,000 people). These include severe blood disorders like agranulocytosis and life-threatening skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The label notes the risk of hepatic encephalopathy in patients with pre-existing hepatic impairment and acute angle-closure glaucoma (frequency not known) as a serious eye concern.

Safety limitations explicitly stated in the regulatory documentation include contraindications in patients with severe renal failure, severe hepatic dysfunction, and known hypersensitivity to Indapamide or other sulfonamide-derived drugs. The risk of electrolyte imbalance requires particular caution, especially in older adults, as these effects can be exacerbated early in treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Indapamid LPH is primarily documented in regulatory sources as an exaggeration of the medicine’s core effect, resulting in severe fluid and electrolyte imbalance. Officially documented manifestations include signs of volume depletion such as profound Hypotension (low blood pressure), Dizziness, Thirst, and neurological symptoms like Lethargy and Mental confusion.


Documented Manifestations and Severe Outcomes

Classification Officially Documented Outcomes
Electrolyte Risks Severe Hypokalemia and Hyponatremia
Cardiovascular Risks Serious Arrhythmias, including the risk of Torsade de pointes
Systemic Risks Progression to Acute Renal Failure or Hepatic Encephalopathy

Required Emergency Actions

The regulatory profile for Indapamide overdose emphasizes that no specific antidote is known. Due to the risk of life-threatening events, including severe hypotension and cardiac arrhythmias, government health authorities mandate that individuals must seek immediate medical attention or contact emergency services upon suspicion of an overdose.

Officially described management involves entirely symptomatic and supportive treatment, with the primary focus on the urgent restoration of fluid and electrolyte balance under close medical and hospital monitoring. In vulnerable populations, such as the elderly, effects like hypotension may be prolonged and require aggressive intervention.

Therapeutic Uses of Indapamid LPH

What Indapamid LPH Treats: Main Uses and Benefits

Indapamid LPH is generally used to address chronic cardiovascular risk and fluid imbalances, and supports long-term health management. It is commonly utilized to help treat high blood pressure and fluid retention.

The primary therapeutic use is the sustained lowering of elevated systolic and diastolic pressure in conditions like essential hypertension. It is also applied across domains that involve symptomatic volume overload, particularly to ease the burden of edema (swelling) associated with conditions such as congestive heart failure. Furthermore, the medication may be relevant for patient contexts involving heightened systemic burden, including those with Left Ventricular Hypertrophy (LVH), and assists with managing risks associated with long-term functional stability.

The medication primarily addresses symptom clusters that may create noticeable physiological strain and provides support that helps ease the overall symptom burden. “It is generally used to help stabilize pressure and manage long-term vascular health.”


Quick Fact: Relief for Elevated Pressure & Edema

Feature Therapeutic Focus
Primary Condition Essential Hypertension
Symptom Cluster Elevated Blood Pressure, Peripheral Edema
Patient Benefit Supports long-term functional stability, helps improve physical comfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The use of Indapamid LPH is defined by specific population criteria and absolute contraindications established in regulatory labeling. The medicine is contraindicated for patients with known hypersensitivity to indapamide or any other sulfonamide-derived drug.

Contraindicated Populations (Mandatory Exclusion)

Absolute prohibitions apply to individuals with severe renal failure (creatinine clearance below 30 mL/min), hepatic encephalopathy or severe liver impairment, and existing hypokalaemia (low potassium). Use is also generally not recommended during pregnancy and lactation.

Age and Conditional Eligibility

The primary approved population consists of adults aged 18 and over. Use is not recommended in children and adolescents as safety and efficacy have not been established due to insufficient data. Treatment of elderly patients is permitted but requires caution and close monitoring, particularly regarding renal function and electrolyte balance.

Conditional use and special monitoring are required for patients with non-severe renal or hepatic impairment, diabetes, gout, or Systemic Lupus Erythematosus. These restrictions ensure that treatment is only pursued under specific and monitored conditions as defined by the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Indapamid LPH is defined by documented interactions related to electrolyte balance, hemodynamic effects, and the potential for increased toxicity of co-administered medicines.

Formally Contraindicated and Not Recommended Combinations

Category Restriction Mechanism and Context
Lithium Co-administration is generally contraindicated. Indapamide reduces the renal clearance of Lithium, resulting in significantly increased plasma lithium levels and the risk of toxicity.
Aliskiren Contraindicated in patients with diabetes mellitus. Combination with Aliskiren in this population increases the risk of severe renal impairment.
Torsades-inducing Agents Use is not recommended. Increased risk of ventricular arrhythmias, particularly Torsades de pointes, due to the hypokalemia induced by Indapamide.

Pharmacodynamic and Exposure-Modifying Interactions

Combining Indapamid LPH with certain medicinal products results in specific additive or opposing effects as documented in regulatory labeling:

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and high-dose Salicylates may cause a loss of antihypertensive effect. This combination also carries an increased risk of acute renal failure, especially in dehydrated patients.
  • ACE Inhibitors (e.g., Ramipril) and Angiotensin Receptor Blockers (ARBs) may cause severe hypotension and risk of acute renal failure when taken by patients who are already volume-depleted.
  • Digoxin and other Hypokalemia-inducing agents (e.g., certain laxatives, systemic corticosteroids) increase the risk and severity of hypokalemia, which can in turn sensitize the heart to Digoxin toxicity.
  • Calcium salts/supplements may lead to elevated serum calcium levels due to Indapamide's documented effect of decreasing urinary calcium excretion.
  • Alcohol (Ethanol) may potentiate the orthostatic hypotensive effect of the medicine, resulting in an additive lowering of blood pressure.

Mechanism of Action

Indapamide LPH is a non-thiazide sulfonamide molecule that induces pathway-specific alterations primarily within the renal and vascular systems.

Modulation of Renal Electrolyte Transport

Its action initiates in the distal convoluted tubule of the nephron, where it functions as a mechanism-based inhibitor of the sodium-chloride cotransporter (NCC). This molecular interaction modifies early steps in ion transport, preventing the apical reabsorption of sodium ( Na^+) and chloride ( Cl^-) into the tubular epithelial cells. This process shifts the osmotic and solute balance, leading to a net change in fluid and electrolyte excretion.

Modification of Vascular Smooth Muscle Parameters

Independent of its diuretic function, Indapamide engages mechanisms that influence peripheral vascular resistance. It modulates calcium ( Ca^2+) flux within the smooth muscle cells of the arteriolar walls, resulting in the attenuation of smooth muscle contraction. This action alters local vascular tone and influences systemic blood flow parameters.

Influencing Local Mediator Activity

Furthermore, the molecule interacts with processes affecting local mediator activity, specifically influencing the production and effects of vasoactive substances like prostaglandins. This supports the regulation of homeostatic feedback loops within the cardiovascular system.

Dosage and Administration Information

How to Use Indapamid LPH

Indapamid LPH is administered strictly by the oral route as a tablet and is intended for long-term use in managing chronic conditions. The medicine is taken once daily (q.d.), typically in the morning, to support consistent daily dosing and minimize nighttime urinary frequency. The tablet may be administered with or without food.

Official Dosing and Adjustment Schedule

For Essential Hypertension, the usual starting dose is 1.25 mg once daily. The dose may be increased to 2.5 mg after a minimum of 4 weeks if the initial dose is insufficient. For volume overload or Edema, dosing typically starts at 2.5 mg once daily. The official maximum daily dose across indications is 5 mg.

Special Administration Requirements

The tablet must be swallowed whole with water. It is a procedural constraint that prolonged-release formulations, such as the 1.5 mg strength, must not be crushed or chewed to preserve their intended rate of release. If a dose is missed, the standard procedure is to skip that dose and take the next dose at the regularly scheduled time; a double dose should not be taken.

Population-Specific Use Principles

Dose selection for older adults (aged ge 65 years) is typically approached cautiously, often initiating at the low end of the approved range. Use is generally not recommended for pediatric patients (under 18 years) due to the lack of established safety and efficacy data in this age group.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indapamid LPH

This overview describes the research that has explored the use of the active ingredient in Indapamid LPH (Indapamide). It focuses on what types of studies have been conducted and what their findings indicate, without offering any clinical advice or making personal predictions.


Evidence for Use in High Blood Pressure (Essential Hypertension)

Studies exploring the active ingredient Indapamide have been conducted using various research designs, including large-scale Randomized Controlled Trials (RCTs) and long-term observational analyses. Research has been applied in studies examining the change in blood pressure levels and the occurrence of major cardiovascular events.

Longer-term research also monitored the observed frequency of major complications such as stroke and cardiovascular death in the studied patient groups. While these findings help contextualize how the active ingredient was observed in large groups over time, the results often apply to a treatment plan where Indapamide was a component in a combination therapy, and research has not yet clearly defined its singular contribution.


Evidence for Use in Reducing Cardiovascular Risk

Research examined the outcomes in patient groups who were already categorized as high-risk, such as those with a history of stroke or who also have conditions like Type 2 Diabetes. These studies used long-term designs to track the observed rate of specific measured clinical outcomes, including cardiovascular death and the composite outcome known as Major Cardiovascular Events (MACE).

Studies report how these specific measured outcomes evolved in the observed populations. For instance, research highlights changes measured during the study period in the rate of stroke across various groups. However, it is important to remember that these findings describe group patterns, not personal outcomes.


Evidence for Use in Fluid Retention (Edema) and Heart Conditions

Research explored the active ingredient in Indapamid LPH for fluid retention, a condition marked by functional limitations often resulting in edema (swelling) associated with Congestive Heart Failure (CHF). The trials primarily looked at short-to-medium-term outcomes related to physical discomfort, such as the change in swelling. Research also explored its use in patients with Left Ventricular Hypertrophy (LVH), where studies monitored changes in heart muscle structure.

Findings describe patterns observed in studies regarding temporary changes measured in fluid markers. However, research for these indications remains limited and heterogeneous, particularly when compared to the volume of data available for essential hypertension.


What is Still Uncertain About Indapamid LPH Research

Several limitations have been noted in the body of evidence:

  • Long-term outcomes are not fully established for all outcomes and patient groups, especially when the active ingredient is used alone (monotherapy).
  • Results apply only to the populations studied, meaning the evidence may be less clear for individuals who do not match the trial participants (e.g., younger patients or those with severe renal disease).
  • Comparative evidence is lacking for direct, long-term outcomes against every type of modern blood pressure medication.
  • Sample sizes were modest in some of the earlier or more focused studies.

Frequently Asked Questions (FAQ)

Common questions about Indapamid LPH (FAQ)


Q: Is Indapamid LPH used for anything other than high blood pressure?

According to official product information, this medicine is primarily used for managing elevated blood pressure. However, regulatory documents also describe its use for treating salt and fluid retention, commonly known as edema, which can be associated with conditions like congestive heart failure.


Q: Can Indapamid LPH be taken by people with kidney concerns?

Regulatory documents state that Indapamid LPH is contraindicated (should not be used) in cases of severe renal failure (a serious kidney concern). For people with less severe kidney function concerns, the official precautions indicate that cautious use and close monitoring are required.


Q: What happens if I stop taking Indapamid LPH suddenly?

Regulatory documents describe that abruptly discontinuing this type of medicine, especially after long-term use, may lead to an unwanted sudden rise in blood pressure or a worsening of an underlying heart condition. Stopping treatment is an action that should be discussed with a healthcare provider.


Q: How quickly should I expect Indapamid LPH to start working?

Studies and official information indicate that the blood pressure-lowering effect begins within 1 to 2 weeks after treatment starts. However, the medicine's full or maximum effectiveness is typically reached only after 3 to 4 months of continuous, consistent use.


Q: Can Indapamid LPH cause electrolyte issues?

Official warnings describe that the medicine can lead to fluid and electrolyte imbalances in the body. These can include low levels of essential electrolytes, such as potassium (hypokalemia), sodium (hyponatremia), and magnesium (hypomagnesemia).


Q: Can older adults safely use Indapamid LPH?

Use in older adults is permitted but is described in official documents as requiring caution and close monitoring. This is particularly important for checking electrolyte balance, as severe imbalances have been reported, primarily in older female patients.


Q: Are there certain foods or drinks that should be avoided while taking Indapamid LPH?

Regulatory information indicates the tablet can be administered with or without food. While specific foods are not generally forbidden, patients are often advised to follow physician-directed special dietary instructions, such as a low-sodium or low-salt diet, to support treatment.


Q: What is the difference between Indapamid LPH and a standard diuretic?

Indapamid LPH is classified as a thiazide-like diuretic and a sulfonamide derivative. Official documents note that it differs from some diuretics by having a mild diuretic effect that is combined with direct action on blood vessels (vasodilation) to help lower blood pressure.


Q: How often do people need blood tests when they start Indapamid LPH?

Regulatory documents state that periodic determinations of serum electrolytes (like potassium and sodium), as well as renal function tests, should be performed at appropriate intervals during treatment. This monitoring is necessary to check for potential imbalances or changes.


Q: Can Indapamid LPH interact with pain relievers like ibuprofen?

Regulatory warnings describe that combining the medicine with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include ibuprofen, may cause a loss of antihypertensive effect. This combination also carries an increased risk of acute renal failure, particularly in patients who are dehydrated.


Q: Does Indapamid LPH cause changes in sleep patterns?

The official side effect listings for the medicine include trouble sleeping (insomnia) and drowsiness as effects. These are listed as less common adverse reactions, reported in fewer than 1 in 100 people.


Q: Does Indapamid LPH have any impact on cholesterol levels?

Regulatory studies indicate that the medicine does not generally interfere with lipid metabolism. This means it is not typically expected to significantly affect levels of triglycerides, LDL-cholesterol, or HDL-cholesterol.


Q: Are there any known interactions between Indapamid LPH and herbal products?

While specific studies on all herbal products are often lacking, regulatory guidance highlights potential concerns when combining the medicine with herbal products that may have a diuretic effect or those that are known to affect potassium levels in the body.


Q: If I experience nausea while taking Indapamid LPH, is this a common reaction?

Nausea is listed in the official documents as a less common adverse reaction to the medicine. This incidence means it is reported to occur in fewer than 1 in 100 people in the studied patient population.


Q: How long does the effect of one dose of Indapamid LPH usually last?

Regulatory studies have demonstrated that the antihypertensive effect of one dose lasts for 24 hours. This duration of action is why the medicine is administered once daily.


Q: Can men experience specific side effects when taking Indapamid LPH?

Official side effect listings for the medicine include reports of decreased interest in sexual intercourse and inability to have or keep an erection. These effects are listed as less common, occurring in fewer than 1 in 100 people.


Q: What is the typical timeframe before a doctor decides if Indapamid LPH is working?

Regulatory guidelines suggest that blood pressure should be reassessed to determine effectiveness 2 to 4 weeks after starting the medicine. If blood pressure control is deemed insufficient, the dose may be reviewed based on regulatory guidelines.


Q: Are there any warnings about taking Indapamid LPH before surgery?

Official prescribing information contains statements regarding the need to inform the doctor or dentist that the medicine is being taken if the patient is scheduled to have any type of surgery, including dental surgery.


Q: Can Indapamid LPH cause changes in vision?

Official documents describe the potential for eye-related effects, including blurred vision (listed as less common). In rare instances, a serious eye condition called acute angle-closure glaucoma is also listed (frequency not known).


Q: Is it necessary to drink extra water when taking Indapamid LPH?

Regulatory warnings focus on the need to prevent dehydration and monitor for signs of fluid or electrolyte imbalance. The label does not universally instruct users to drink extra water, but avoiding dehydration is a key safety point.


Q: Are there known cases of allergic reactions to Indapamid LPH?

The medicine is contraindicated in patients with a known hypersensitivity to the drug or other sulfonamide derivatives. The official safety profile also lists severe allergic reactions, such as angioedema and severe skin conditions, as very rare adverse reactions.


Q: What are the general guidelines for using Indapamid LPH in adolescents?

Regulatory documents state that the medicine is not recommended for use in children and adolescents (under 18 years). This guidance is provided because safety and effectiveness have not been adequately established in this age group.


Q: Is Indapamid LPH a medication that needs to be taken indefinitely?

For the treatment of elevated blood pressure (hypertension), regulatory information indicates that treatment is typically intended to be life-long for the management of chronic high blood pressure.


Q: Does the efficacy of Indapamid LPH change over time?

Regulatory evidence indicates that no loss of efficacy (tachyphylaxis) is expected to occur during long-term continuous use of the medicine for essential hypertension.


Q: Can someone who has gout use Indapamid LPH?

The medicine is associated with the potential for increased uric acid levels (hyperuricemia), which may precipitate gout flares in susceptible individuals. The official precautions require monitoring of uric acid levels during treatment.


Q: Is the low-dose formulation of Indapamid LPH less likely to cause side effects?

Official documents describe that the incidence and severity of certain dose-related side effects, such as low potassium (hypokalemia) and low sodium (hyponatremia), are reported to increase with higher doses of the medicine.


Q: What are the official cautions about operating machinery while on Indapamid LPH?

Official warnings state that a temporary impairment to the ability to drive or operate machinery may occur due to side effects like dizziness or tiredness. The official caution applies until the individual is certain the medicine does not affect their ability to concentrate or react.


Q: Are there regulatory summaries discussing research into Indapamid LPH for heart conditions?

Research summaries have examined the potential for the active ingredient to provide cardiovascular protection beyond just blood pressure control. This includes studies observing the reduction of left ventricular hypertrophy (thickening of the heart muscle).


Q: Is Indapamid LPH appropriate for people who have diabetes?

Official warnings state that treatment of patients with diabetes requires close monitoring of blood sugar. The medicine may cause latent diabetes to become manifest or potentially require changes to existing diabetic medication.


Q: Is it true that Indapamid LPH can affect blood sugar?

Regulatory documents indicate that the medicine may affect glucose tolerance. This includes the potential for causing latent diabetes to become manifest and the requirement for routine monitoring of blood sugar levels.


Q: Why is Indapamid LPH sometimes called a 'thiazide-like' diuretic?

The classification as thiazide-like is due to two factors: its chemical structure, as it is a sulfonamide derivative with an indole ring, and its mechanism of action, which is similar to thiazides by inhibiting sodium reabsorption in a specific part of the kidney.


Q: How does Indapamid LPH differ from hydrochlorothiazide in official documents?

Official documents, such as the FDA drug label, include data comparing the incidence of hypokalemia (low potassium) between Indapamide and hydrochlorothiazide at specific doses. However, they do not offer a comprehensive conclusion on overall superiority.


Q: What should be done if I experience persistent muscle cramps while on Indapamid LPH?

Official safety information lists muscle cramps as a potential clinical sign of a fluid or electrolyte imbalance, such as low potassium (hypokalemia). These signs are noted to indicate a need for monitoring.

How should Indapamid LPH be stored and disposed of?

How to Store and Dispose of Indapamide LPH

Official regulatory guidelines require Indapamide tablets to be stored under controlled conditions to maintain product stability and quality.

Storage Requirements

Indapamide must be stored at room temperature, generally below 25 C or 30 C, and must be kept from freezing. The medicine must be protected from moisture and direct light and should remain in its original container or blister pack, kept tightly closed. For safety, the product must be stored out of the sight and reach of children.


Disposal Instructions

Do not dispose of unused or expired Indapamide in drains or wastewater systems. Unwanted medicine must be handled as pharmaceutical waste. Patients should return the product to a pharmacist or follow specific local regulations for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indapamid LPH found in:

A-Z Index: